Page 12 - Flipbook

Germline HRRm Testing Only Will Miss Patients

with Somatic Mutations

• Whole-blood testing identifies germline but not somatic mutations

• 50% or more of the BRCA HRR gene alterations present in mCRPC may be somatic in origin
• Testing for germline mutations only would miss a large proportion of patients with a mutation, who could benefit from

PARP inhibitor treatment

• ctDNA and tumour testing capture patients with both germline and somatic mutations
• ctDNA analysis provides both somatic and germline data because the germline is used as a reference. If likely germline alterations are detected, patients may be reflex
germline tested

Whole-blood testing will ctDNA and tumour testing
not identify all patients give the opportunity for all

with an HRR mutation patients with an HRR

mutation to be identified

ctDNA, circulating tumour DNA; mCRPC, metastatic castration-resistant prostate cancer; HRRm, homologous recombination repair mutation
Abida W et al. JCO Precis Oncol. 2017;1:1-16.